My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

Vor Biopharma Inc. - Common Stock (NQ:VOR)

7.750 -0.580 (-6.96%)

Streaming Delayed Price Updated: 11:32 AM EST, Dec 1, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Vor Biopharma Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >

Top movers analysis one hour before the close of the markets on 2025-11-11: top gainers and losers in today's session. ↗

November 11, 2025

Intrigued by the market activity one hour before the close of the markets on Tuesday? Uncover the key winners and losers of today's session in our insightful analysis.

Via Chartmill

Let's take a look at the stocks that are in motion in today's session. ↗

November 11, 2025

Curious about what's happening in today's session? Check out the latest stock movements and price changes.

Via Chartmill

Dow Gains More Than 300 Points; Energy Vault Holdings Shares Jump ↗

November 11, 2025

Via Benzinga

Topics Stocks

Vor Bio Stock Jumped 19% Today And Retail Investors Are Eyeing A Breakout Rally: Here’s What’s Happening ↗

August 13, 2025

Via Stocktwits

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

November 11, 2025

Via Benzinga

Let's uncover which stocks are experiencing notable gaps during today's session. ↗

November 11, 2025

The market is filled with gapping stocks in Tuesday's session. Let's discover which stocks are showing gap-ups and gap-downs.

Via Chartmill

Vor Biopharma Secures $100 Million Offering After Reporting Efficacy In Kidney Disease Trial ↗

November 11, 2025

Vor Biopharma prices $100 million share offering as partner RemeGen reports strong Phase 3 results for telitacicept in IgA nephropathy.

Via Benzinga

US Stocks Mixed; Sea Shares Gain After Q3 Results ↗

November 11, 2025

Via Benzinga

Get insights into the top gainers and losers of Tuesday's pre-market session. ↗

November 11, 2025

Wondering what's happening in Tuesday's pre-market session? Find an overview in this article.

Via Chartmill

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

November 11, 2025

Via Benzinga

Why Rocket Lab Shares Are Trading Higher By Over 9%; Here Are 20 Stocks Moving Premarket ↗

November 11, 2025

Via Benzinga

These stocks are moving in today's after hours session ↗

November 10, 2025

After the conclusion of the US market's regular session on Monday, let's examine the after-hours session and unveil the notable performers among the top gainers and losers.

Via Chartmill

12 Health Care Stocks Moving In Monday's After-Market Session ↗

November 10, 2025

Via Benzinga

Novartis Strengthens Kidney Disease Pipeline With Promising Data ↗

October 16, 2025

Novartis' Fabhalta showed significant efficacy and safety in a Phase 3 IgA nephropathy study, supporting regulatory filings planned for 2026.

Via Benzinga

Vor Bio's Collaborator Delivers Positive Results For Telitacicept In Autoimmune Disorder That Impacts Tears ↗

October 14, 2025

Telitacicept showed strong efficacy and safety in a 48-week Phase 3 trial for Sjögren's disease, meeting all primary and secondary endpoints.

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Intraday Session ↗

October 01, 2025

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

September 30, 2025

Via Benzinga

FDA Eases Monitoring Burden For Kidney Disease Patients On Travere Therapeutics' Filspari ↗

August 28, 2025

FDA eases REMS labeling for Travere's Filspari, reducing liver monitoring and removing embryo-fetal toxicity rules, with FSGS approval review ongoing.

Via Benzinga

Vor Bio's Investigational Drug Scores Phase 3 Win In Autoimmune Kidney Disease Trial ↗

August 27, 2025

Vor Bio partner RemeGen reports Phase 3 success for telitacicept in IgA nephropathy, showing a 55% drop in proteinuria and plans for a China BLA filing.

Via Benzinga

Vor Bio Rallies On Strong Data For Autoimmune Drug Candidate ↗

August 13, 2025

Vor Bio shares climb as RemeGen's Phase 3 study in China shows telitacicept improves disease activity in primary Sjögren's disease.

Via Benzinga

12 Health Care Stocks Moving In Friday's Intraday Session ↗

July 11, 2025

Via Benzinga

Why ENDRA Life Sciences Shares Are Trading Higher By Over 61%; Here Are 20 Stocks Moving Premarket ↗

July 08, 2025

Via Benzinga

Top stock movements in today's session. ↗

July 07, 2025

Curious to know what's happening on the US markets one hour before the close of the markets on Monday? Join us as we explore the top gainers and losers in today's session.

Via Chartmill

12 Health Care Stocks Moving In Monday's Intraday Session ↗

July 07, 2025

Via Benzinga

Here are the top movers in Monday's session. ↗

July 07, 2025

Let's have a look at what is happening on the US markets in the middle of the day on Monday. Below you can find the top gainers and losers in today's session.

Via Chartmill

Top stock movements in today's session. ↗

July 03, 2025

Let's have a look at what is happening on the US markets one hour before the close of the markets on Thursday. Below you can find the top gainers and losers in today's session.

Via Chartmill

12 Health Care Stocks Moving In Thursday's Intraday Session ↗

July 03, 2025

Via Benzinga

These stocks have an unusual volume in today's session ↗

July 01, 2025

On Tuesday, there are stocks with unusual volume. Let's take a look.

Via Chartmill

Let's take a look at the stocks that are in motion in today's session. ↗

June 30, 2025

Stay up-to-date with the latest market trends one hour before the close of the markets on Monday. Explore the top gainers and losers during today's session in our detailed report.

Via Chartmill

Vor Biopharma's RemeGen Deal Paves Way For Multi-Billion Dollar Autoimmune Market ↗

June 30, 2025

Vor Biopharma gains rights to autoimmune drug telitacicept, raises capital and names a new CEO in a major strategic reset.

Via Benzinga

< Previous 1 2 3 4 5 6 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.